- Home
- CYBR vs OCEAW Comparison
CYBR vs OCEAW Comparison
Compare CYBR & OCEAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBR
- OCEAW
- Stock Information
- Founded
- CYBR 1999
- OCEAW N/A
- Country
- CYBR Israel
- OCEAW United States
- Employees
- CYBR N/A
- OCEAW 7
- Industry
- CYBR Computer Software: Prepackaged Software
- OCEAW Biotechnology: Pharmaceutical Preparations
- Sector
- CYBR Technology
- OCEAW Health Care
- Exchange
- CYBR Nasdaq
- OCEAW Nasdaq
- Market Cap
- CYBR N/A
- OCEAW N/A
- IPO Year
- CYBR 2014
- OCEAW 2021
- Fundamental
- Price
- CYBR $325.84
- OCEAW $0.02
- Analyst Decision
- CYBR Strong Buy
- OCEAW
- Analyst Count
- CYBR 33
- OCEAW 0
- Target Price
- CYBR $403.64
- OCEAW N/A
- AVG Volume (30 Days)
- CYBR 758.6K
- OCEAW N/A
- Earning Date
- CYBR 05-13-2025
- OCEAW N/A
- Dividend Yield
- CYBR N/A
- OCEAW N/A
- EPS Growth
- CYBR N/A
- OCEAW N/A
- EPS
- CYBR N/A
- OCEAW N/A
- Revenue
- CYBR $1,000,742,000.00
- OCEAW N/A
- Revenue This Year
- CYBR $34.10
- OCEAW N/A
- Revenue Next Year
- CYBR $19.82
- OCEAW N/A
- P/E Ratio
- CYBR N/A
- OCEAW N/A
- Revenue Growth
- CYBR 33.10
- OCEAW N/A
- 52 Week Low
- CYBR $223.41
- OCEAW N/A
- 52 Week High
- CYBR $421.00
- OCEAW N/A
- Technical
- Relative Strength Index (RSI)
- CYBR 44.10
- OCEAW N/A
- Support Level
- CYBR $306.00
- OCEAW N/A
- Resistance Level
- CYBR $359.54
- OCEAW N/A
- Average True Range (ATR)
- CYBR 19.83
- OCEAW 0.00
- MACD
- CYBR 0.59
- OCEAW 0.00
- Stochastic Oscillator
- CYBR 52.48
- OCEAW 0.00
About OCEAW Ocean Biomediacal Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.